Kidney international

Safety of semaglutide in people with different levels of chronic kidney disease in the FLOW trial

Updated

Abstract

Medication intolerance and side effects may worsen in people with type 2 diabetes and chronic kidney disease as estimated glomerular filtration rate decreases.

  • This analysis focused on the safety of semaglutide in individuals with varying baseline levels of kidney function.
  • A lower estimated glomerular filtration rate is associated with increased medication intolerance and side effects.
  • Findings from this assessment could inform treatment decisions for patients with type 2 diabetes and chronic kidney disease.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free